# Qualia Life Sciences Creating meaningful and sustainable upgrades to personal well-being ## Elevator pitch Founded in 2015, our mission is to create best in class well-being products by employing a unique methodology to research and development based on complex systems science. Rather than overriding regulatory systems with chemicals designed to move a biomarker in a particular direction, this approach focuses on supporting the body’s ability to self-regulate. - Canonical URL: https://wefunder.com/neurohacker - Entity ID: wefunder:company:15182 - Last updated: 2026-06-06T05:00:41Z - Generated at: 2026-06-07T03:41:25Z ## Quick facts - PURPOSE: Mission driven wellness company with premium products across desirable categories. - GROWTH POTENTIAL: $578 Billion global market (2025) with 8.8% CAGR. - SCIENCE: Unique approach to science-backed product development. - TEAM: Top scientists, MD/PhD advisors, biohackers, investors and loyal customers contribute to product ideation, formulation and testing. - RECURRING REVENUES: Proven, profitable subscription model with attractive margins. - MULTI-CHANNEL SALES: Direct-to-consumer, wholesale, practitioners, and Amazon. - OPERATIONAL EXCELLENCE: Over $20M in lifetime sales; profitable in 2019 (on EBITDA basis). ## Active fundraises - wefunder:fundraise:29942: 506(c) successful (USD) - wefunder:fundraise:29172: 4(a)(6) successful (USD) - wefunder:fundraise:24404: 4(a)(6) successful (USD) - wefunder:fundraise:20558: 506(c) successful (USD) - wefunder:fundraise:18654: 4(a)(6) successful (USD) - wefunder:fundraise:10601: 4(a)(6) successful (USD) ## Story Neurohacker Collective aims to provide meaningful scientific advances through a deeper understanding of human biology. We started with supplements for the mind (known as “nootropics”), which is a rapidly growing industry with global sales of $1.35 billion and expected growth to $6.1 billion by 2025. In the creation of our Qualia nootropics product line, we set out to make a supplement radically different than all other nootropics on the market. Many nootropics focus only on short-term effects. Instead of focusing on improving a single aspect such as memory, Qualia addresses long-term brain health and encourages new neuron and synapse development for a stronger brain.While choosing from hundreds of ingredients that could serve our purpose, we took into account how a set of ingredients, as a whole, would support each physiological outcome we wanted to promote and the cognitive and subjective outcomes we sought to enhance, as well as general effects on the rest of the body. This careful and laborious formulation process lead to the creation of Qualia Mind that has unquestionably established itself as the market leader. With abundant support from some of the world’s most recognized and respected doctors, healthcare practitioners, scientists, health and wellness leaders and our customers, our revenues continue to climb with 91% of product revenue being subscription-driven (excluding Amazon and wholesale). The reason our company has a uniquely explosive value potential is that our complex systems science modeling (which can't be easily replicated by other wellness companies without the brain trust we've assembled) can be applied to a bevy of products. This has us positioned to create best in class supplement products across a variety of health needs in the near future, in an industry estimated to be worth 578 billion dollars within 5 years. We are also planning to develop solutions for sleep, anxiety/mood, pain, immune function, fitness performance, hormone balancing, and cardiovascular health.$20,000,000+ in Total Sales So FarGrowing Revenues and Profit ContributionRevenues and Profit Contribution Margin by bi-annual period. Profit Contribution is defined as sales revenues less costs of goods and advertising expenses. In 2019, Neurohacker reached profitability (on EBITDA basis).A World-Class Product Development EngineWe are deeply focused on the complex systems modeling necessary to deliver real efficacy at scale in the nutraceutical space, always with the overarching intention to support the human body’s natural ability to regulate while working to help increase its capacity. TOP SCIENTISTS & MDS: Our products are developed by top scientists in complex-systems modeling, neurobiology, organic chemistry as well as dozens of MDs and PhDs.RESEARCH-BACKED INGREDIENTS: All our ingredients are chosen based on the strong empirical basis of their safety.FULL TRANSPARENCY: We are 100% transparent. No proprietary blends. We fully publish the research behind every product.PURITY & POTENCY: We take great care to use the most potent, high-purity, and bioavailable forms of each ingredient that are gluten-free and non-GMOWe Have 6 Products, By the End of 2020 We Plan to Have at Least 8Radical Cognitive EnhancementQUALIA FOCUS & QUALIA MIND are premier, research-based nootropics that help support mental performance and brain health. Specifically designed to promote focus, support energy, mental clarity, mood, memory, and creativity.  In addition to immediate neurochemical and physiological effects, Qualia nootropics go a step further addressing long-term cognitive health benefits.Pilot Study Using Qualia Mind Shows Meaningful Positive ResultsThe results for 23 eligible subjects revealed meaningful improvement in core cognitive areas of reasoning, verbal ability and concentration. After 5 days of taking Qualia Mind, participants saw an average 85.4% increase in scores to measure ability to concentrate/avoid distraction, 37.2% increase in scores for planning skills, 31.1% increase in scores for visual representation, 16.9% increase in scores for verbal reasoning, 13.3% increase in scores for verbal short-term memory, and 10.2% increase in scores for episodic memory. Given that this study did not have a placebo control, we cannot conclusively determine whether or not Qualia Mind is the cause of the increased scores. See additional details on the study here. We are in the process of conducting a double-blinded, placebo-controlled clinical study of Qualia Mind to confirm these results.Eternus: Our Breakthrough in AgingEternus, is specifically designed to combat the aging process in the most comprehensive way ever developed from a supplement product. Eternus 36+ high-purity and powerful nutrients to boost NAD+, ATP, & AMPK production, support mitochondrial fitness & cell energy, amplify productivity, promote restful sleep, upgrade energy levels, and provide support for handling stress. More cell energy leads to sounder sleep, increased productivity, better workouts, more capacity to handle stress, enhanced cognitive performance, and an overall whole-system upgrade.Qualia Nootropic Energy Shots: The Future of EnergyWhen you are tired and low on energy, even the simplest task seems like an enormous burden. Thinking, acting, and even feeling is difficult when your energy is low. Pound for pound the brain uses the most energy of any organ. There are many energy shots, drinks, and so-called energy solutions but none are as firmly rooted in supporting the organ that needs the energy the most, your brain, than Qualia Nootropic Energy. Our shot delivers 12 high-purity nutrients to enhance your energy and brain health. Take it every day or just when you need to perform at your peak.Doctors, Scientists, Health, and Fitness Leaders Love NeurohackerOur mission and complex systems formulation approach is attracting thought leaders and researchers from leading institutions from around the world from diverse fields — psychology, neurobiology, fitness, wellness, technology, and medicine.Neurohacker Collective’s Next StepsWe look to provide people with the products, resources, and tools they need to help their whole being — mind, brain, and body — work together in harmony. Our expanding product development team comprised of doctors, neuroscientists, and chemists have identified product opportunities where we can use our unique formulation process to deliver category-defining products to the market for each category. As our company grows and the science evolves we are committed to continuing to develop best in class products to enhance human well-being. Product RoadmapOur Customers Are Passionate About UsWe’ve developed our products with potent, high-purity, and bioavailable forms of each ingredient and our customers love that. Qualia nootropics are used by some top personalities in the fields of science, sports, academia, and business including: Jason Silva, Mark Divine, Ben Greenfield, Jamie Wheel, Dr. H. Mcllroy, Dr. J. Becker, Dr. Hyla Cass and more.Founder InterviewsJames Schmachtenberger Chief Executive Officer of Neurohacker CollectiveJames knows the potential of cognitive optimization firsthand. Here, he explains the neurological and physiological struggles he experienced at the dawn of his ambitious career, and the life-changing event that sparked his vision for Neurohacker Collective.Daniel Schmachtenberger Chief Strategy Officer of Neurohacker CollectiveDaniel's understanding of complex systems and whole systems science is distinct from reductive science. Here, he explains the approach we are using to address humanity's most challenging issues of human capacity.Jordan Greenhall Executive Chairman of Neurohacker CollectiveJordan has led startups to enormous successes before. Here, he explains why he chose Neurohacker Collective as his next venture, and gives a detailed analysis of the success we've already had, and our collective philosophy for fundraising. ## FAQ 1. **Being a user of your product and a fan of crowd sourcing, I was pretty excited to see you guys pop on WeFunder. My question for you is, how did you come to a valuation of $20 million? I feel like the valuation is rather high and brings a chance for return on investment could b...** - Thanks! To answer your first question, requires looking at NHC from two directions. From the bottom, we look at valuation in terms of the stage the company has reached. In classic startup terms, we’ve blown through the first few startup gates; i) creating an awesome team, ii) launching a an alpha product, iii) first revenues, and iv) evidence of potential to scale with a mix of existing and burgeoning revenue generating channels. With more than $2M in the trailing twelve months and a high gro... 2. **I'm with Hunter on the $500 minimum and with Barnaby on not being a fan of SAFEs for non-tech startups. A convertible note or straight equity would be better. The SEC outlines some very good concerns with the inappropriateness of SAFEs for certain investments here https://www....** - Fundamentally, we believe the opportunity we're offering here is more about the vision, team, traction, and market opportunity, and less about boiler plate documents. For clarity, the SAFE agreement is a doc designed for and by the the startup marketplace by venture investors as a standard by which early-stage, or seed investors and founders could move quickly and effectively towards agreement. As noted by the SEC in the Bulletin that you refer to the various mechanisms of the SAFE were desig... 3. **$1,000+ Membership in our product Beta test group... Will we get to test new products for free? Approximately how long will testing periods be? Does each tier include the previous tier perks?** - Hi Jeromi. Yes, you will get to test new products for free. Testing periods will vary widely by the kind of product and the stage of testing. You can sign up for as much or as little as you like. Yes, the tiers are cumulative! 4. **Are there any financials to look at? Current and/or projections...** - Hi Lev, you can find the complete 2016 financials on the Form C. https://www.sec.gov/Archives/edgar/data/1707359/000167025417000170/document_4.pdf For 2017, I recommend you expand the various Q&A questions above and look at the financially targeted ones. Good data to be found there. 5. **It seems like your team is largely comprised of entrepreneurs and marketing professionals. What medical credentials does your team have, and what safeguards have you put in place to ensure this is a scientifically vetted product, and not just we'll branded snake oil? Asking as...** - Hey Keith, our Website has a better view into the deeper scientific/medical team behind the collective: http://neurohacker.com/ethos/ Some specific people of note: Dan Stickler, MD was a surgeon and got into longevity medicine and the nootropics space. Andrew Huberman, PhD, Stanford School of Medicine Sara Adaes, PhD in neurobiology is a full time contractor doing research for Neurohacker Collective. Shawn Ramer, PhD biochemist with pharma and healthcare experience is an advisor we brought on... ## Team - James Schmachtenberger (CEO) - Jordan Greenhall (Executive Chair) - Hakan Lindskog (Chief Operating Officer) - Shawn Ramer (Senior Vice President, Product Development) - Greg Kelly, ND (Lead Product Formulator) - Dan Stickler, M.D. (Medical Director) - Mark How (Chief Revenue Officer) - Lauren Alexander (Vice President, Marketing) - Gk Parish-Philp (Vice President, Technology) - Ben Seeman (Vice President, Wholesale Sales) - Sara Adaes, Ph.D. (Scientific Researcher) - Justin Schilf (Creative Director) - Ben Cote (Director of Community) - Jodi Geigle (Community Experience Manager) - Jennifer Norton (Production Manager) ## Recent posts - You Have Less Than 48 Hours Left To Own Equity In Neurohacker Collective, And We Have An Exciting Announcement For Why You Should! (2020-03-12T10:01:34Z) - It’s Our Campaign’s Final Few Days, And A Lot Hangs In The Balance. Let Us Explain Why. (2020-03-11T03:27:49Z) - The Final Days Of Our Nearly 2 Million Dollar Wefunder Campaign Are Here! Invest Now For Your Last Chance To Own Equity In Neurohacker! (2020-03-03T16:14:17Z) - Your Funding Has Enabled One Of The Best Educational Podcasts On The Planet! (2020-02-24T19:27:56Z) - Big Retail Announcement: Major Stores & Wellness Sites Now Carrying Our Products! (2020-02-17T13:22:43Z) - We're Nearing Wefunder Records With Almost 2 MILLION Raised! This Product Roadmap Explains Investor Excitement! (2020-02-10T23:28:30Z) - This Is My Personal Health Crisis That Led To Neurohacker Collective. (2020-02-04T03:34:52Z) - Clinical Trial News & How To Help Us Show The World What Our Products Can Do! (2020-01-28T19:30:10Z) - Look What Your Funding Did! Then Take Advantage Of Our Final Public Round! (2020-01-21T01:13:14Z) - With Less Than 2 Days Left, Consider Joining Our Mission. (2019-05-29T22:09:02Z) - LAST CALL For Investment! And A Preview Of Our Product Roadmap! (2019-05-28T19:07:42Z) - Investment Round Is CLOSING! Hurry If You Want A Stake In Neurohacker! (2019-05-20T18:54:12Z) - Neurohacker Launches Premium Energy Shot This Autumn After Strong Survey Results (2019-05-14T08:08:31Z) - Investor Update Q1 2019 (2019-05-10T23:06:04Z) - Neurohacker Launches Product Lineup On Walmart.com (2019-05-07T01:19:42Z) ## Q&A - Q: Could you provide an update on when I might start seeing returns on investment? - Q: How do I redeem my investment perk? - A: Hi Mitch. You should have received a message from us already about your perks. If you didn't get that please send an email to support@neurohacker.com. Thank you! - Q: Hi, I'd would love to invest in NC! Am I too late? Can you please clarify all the following: 1) Length, dates & conditions of next investment round. 2) Would I become a shareholder if I invest? 3) Are there any limitation on investing from outside the US? 4) Min/max sums to invest. 5) What are the financial plans for the future? 6) Are you planning to become public/go to the stock exchange? 7) What exactly are the POINTS investors get? 8) What exactly is SAFE note you referred to in other question below? 9) Are you planning to ship to Israel? 10) I cannot see an "Invest" button, why? 11) How exactly is the dividends return planned to work out? 12) Very important: Why wouldn't any another company just copy your formulas if they are out there for all to see? What protects that? Please elaborate as much as you can on all these questions, as simply as possible. Many thanks! Ben - Q: I'm not a fan of SAFE agreements for non-tech start-ups. Here's an excerpt from your Form C explaining just some of the concern: "...In certain circumstances, such as the sale of the company, an initial public offering or dissolution or bankruptcy, holders may only have a right to receive cash to the extent available, rather than preferred stock or other securities. In addition, if the SAFEs are so converted, the holders will lose any rights and preferences of the SAFEs that are not included in the terms of our preferred stock.We are under no obligation to convert the SAFEs into preferred stock. We may never receive a future equity financing or experience a liquidity event, in which case, the holders could be left holding the SAFEs indefinitely. Unlike convertible notes and other securities convertible into or exchangeable for preferred stock, the SAFEs do not have any “default” provisions permitting the holders to demand repayment. We have the discretion as to whether or not to enter into a transaction that causes the conversion of the SAFEs into preferred stock, and the holders have no right to demand such a conversion....". Offering stock, a Convertible Note or Units in an LLC would be much more attractive from an investor point of view. Wish you all the luck in a very tough industry. Let me know if you decide to modify your offering please! - Q: Hi James. I invested in the 2017 round because I worked with Jordan, Mark (How), GK and Ben at DivX. Is there somewhere where you have discussed your exit strategy or, if not, can you tell us what you are building towards in terms of investor returns / exit? - A: Brad, Thank you for your question. Currently we are focused on building shareholder value by growing revenues and profitability. We are not actively considering an exit. However, given our current elevated growth rate (22% in Q2!), we anticipate that Neurohacker will become an attractive acquisition target for strategic investors in the next 2-5 years. Depending on capital needs and market conditions, a public offering could be another option. As always, although prospects are bright at this point, there are no guarantees that we can execute a successful exit. Thank you for your support, Brad! - Q: Hello! It's been quite some time since there have been any updates on this page. As an investor, I'm eager to know what the Company's next steps are and your plans concerning the IPO. Thank you! - A: Hello, Faryal; I apologize for the delayed response. We recently saw your question when posting an update on the platform today! Thank you for your question! We post quarterly updates to our investors here on the Wefunder platform. The most recent one was posted today. It offers a comprehensive review of our results, major developments, and future plans. As for an IPO or other liquidity event, we have no firm plans at this point. For the time being, we are focused on building shareholder value to maximize the outcome in a future liquidity event. If you have further questions after reading our Q4 update, please let us know. Thank you for your interest! - Q: Is there any fund raising round in coming future? - A: Hi Roshan. Thank you for reaching out! At the moment, the company is in a strong enough financial position to fund its upcoming growth initiatives so we're not planning for another funding round soon. However, there are some large growth initiatives we're working on and if they come to fruition they'll likely require additional capital to execute so that could speed up our next funding round. Thank you - Q: I am interested in investing in Qualia Company, I just don’t full understand the perks once invested. What do I get for my money? Thanks. - A: Hi Michael. Thank you for your interest in investing! When you invest in us through WeFunder you will receive equity in the form of a SAFE Note. Once we raise a fixed-price funding round, that will cause the equity (SAFE notes) of the WeFunder investors to convert into preferred units of our company. From there you'll be eligible to participate in any profit distributions if we issue them and will be able to participate in the upside from the potential exit of the company. In addition to owning a piece of the company, we also provide additional perks for investing. These perks depend on the amount you invest and are mostly oriented around receiving free product. If you invest $500 you get a free bottle of the product of your choice. With higher amounts you get a subscription, etc. - Q: Your product packaging is incredible, but it feels wasteful. I really like Daniels take on systems thinking and the circular materials economy, so I was wondering what steps your company will take towards zero waste? - A: Hi Paul. This is a great question! My goal is for Neurohacker to become a company with zero waste. Unfortunately there are a number of factors related to supply chain that make that very difficult to accomplish until we have more scale. When we started the company we did an assessment on whether using plastic or glass bottles was better for the environment. I had expected the answer to be glass but by the time we factored in the additional plastic needed to bubble wrap the glass, the additional fuel usage for shipping due to increased weight, etc. it turned out that plastic was the more environmentally friendly choice. We're currently working with our packaging suppliers to explore options around bio-plastics. So far we haven't found anyone who's making the types of bottles we need in a bio-plastic but we're looking into the potential of custom production runs that would allow us to accomplish this. We're currently in a process of reviewing our packaging from both a design and materials stand point and trying to see what improvements we can make. We're still not large enough as a company for some of the things that I'd like us to do but it looks like we're probably large enough to start getting much of our packaging materials through more eco-friendly methods. - Q: James, there were several questions regarding proposed ROI. With any IPO I have enetred, there was some proposed return, even if speculative. The belief in the product is one thing, ROI is another. If this was answered rpior, please forgive me. Steve - A: Hi Steve. Thank you for your question. The question of ROI is a very difficult one to answer since there's still a lot that's unknown about our growth path. We know clearly that we're growing at a healthy rate year over year but we haven't yet determined what our exit plan is. We may very well IPO at some point but it's also just as likely that we'd be acquired and never go public. Investing in a company pre-IPO it's a bit easier to determine likely ROI since there's usually already been an established price set for the IPO so you can assess the difference of the amount you're investing at vs the anticipated IPO price. We're not entertaining the idea of an IPO at this phase. Though it could very well make sense, it almost definitely wouldn't until we're substantially larger since there's a lot of ongoing expenses associated with going public. When investing through WeFunder you're banking on the idea that the company's value will go up (hopefully substantially) from the value at which you invested and you'll get to participate in all of that upside. I wish I could give a more exact answer but legally we're limited around making commitments on what an anticipated ROI will look like. - Q: I invested early on in company, 1000.00. Not sure where that stands. Being a sleep medicine specialist, with connections with the sleep depot at UCD Medical School in Sacramento, as well as Northstate Medical, I have some input with a large network of innovative physicians . Curious about the sleep products, I understand the mechanics of sleep and lecture to dentists and physicians. Always looking for innovation. Big question, where is my 1k parked? In Warrants?? Fine if so. I just never see investment info until fundraising rounds. Great promise. Touch base. Tim, Mickiewicz, D.D.S. - A: Hi Tim. Thank you for your previous investment! We send quarterly investor updates to all of our investors in addition to the updates we do through the WeFunder platform. If you haven't been receiving them there may be something wrong with the email we have on file for you. You can email support@neurohacker.com and we can look into that for you. We haven't converted any of the WeFunder investments into equity yet so your investment should still be listed on the cap table as a convertible note until we reach our conversion triggers. As far as sleep products go, we're hopefully getting close to bringing our first product to market. We're taking a very different approach than is typical with the development of this product. Rather than focusing on sedation, we're focusing on providing the nutrients needed for optimizing sleep performance and supporting maximum recovery during sleep. We've done some initial testing with one of our Beta groups and got very positive results. We're currently in the middle of a larger test to confirm results and will be making decisions soon on whether the product is ready for market or if additional research is needed. I'll let our science team know about your involvement with the Universities. Maybe there's the ability to explore a study through one of the universities. - Q: Hello James, I am a current investor and received the email notification regarding this final round. Plainly speaking, what is the company’s exit strategy? How long will you remain private? And what is the timeline? Like all investors I am anxious to receive a healthy ROI. These questions will help me to determine how much I will further invest in this final round. Thank you. - A: Hi Sparkle. Thank you for your question and thank you for your prior investment! As far as exit strategy, there's 3 primary directions that we've considered. The first is to get acquired by a larger company that wants to continue the work and research that Neurohacker has started. This is probably the most likely option though we haven't begun actively pursuing this as we're currently still focused on growth more than exit. We've also considered staying private and beginning to pay out profit distributions to our shareholders once we're large enough that our cash flow allows for the ability to fund both growth and profits. Lastly, we've been courted by some investment bankers to go public. We're clear that this isn't something we would do right away as we're not large enough as an organization yet for this to make sense. However we could be within relatively short order based on the growth curves that we're seeing. As with any startup it's near impossible to predict exactly how we'll exit or the timing on it but given where we currently are as a company I'd expect an exit to happen in approximately 2-5 years. - Q: What is your stance on dealing with liver health. Since a lot of nootropics get processed in the liver, is there anything you do to combat any strain on the liver? - A: Hi Josh. Nootropics are not alone; one of the liver's main jobs is processing and transforming compounds. It does this to compounds in the diet, molecules made in the course of normal metabolism, medications, toxins, etc. Many of the nootropic compounds included in Qualia (as well as ingredients in our new product Eternus) support the liver. Choline (as alpha GPC and Citicoline) is an example. The most common chronic liver disease is fatty liver. Chris Masterjohn has written several excellent articles on it. He's convinced that sub-optimal intake of choline is a huge part of the problem (https://chrismasterjohnphd.com/blog/2010/11/28/does-choline-deficiency-contribute-to/). We use two forms of choline in Qualia Mind (1 in Focus) along with several other nutrients (uridine as an example) that facilitate the choline cycle, which is important for both the brain and liver. Nutrients like PQQ, niacinamide and acetyl-L-carnitine are mitochondrial nutrients: they support mitochondrial function in all cells, brain and liver included. The coffee berry we use as a source of caffeine, similar to coffee, because of also including coffee polyphenols, is liver supportive. Artichoke, long before being thought of as a nootropic, was used for liver function by naturopathic doctors and herbalists. These are just a few examples. But the key point is that the brain, like the liver, makes many of the molecules it needs locally and is a very metabolically active tissue. Because of this, there's a big overlap of compounds that help both perform better. We give preference to ingredients that do more than one thing (we use a whole systems science approach). One result of this philosophy is that the nootropics we focus on tend to be things that support better liver health as well as brain performance. - Q: Just enquiring about a recent look into your Amazon reviews through a site called fakespot: https://www.fakespot.com/product/qualia-mind-from-the-neurohacker-collective-premium-nootropic-supplement-for-mental-performance-brain-health-designed-to-optimize-brain-function-increase-focus-mental-clarity-boost - A: Hi Nathan. That one's hard for me to speak to since I'm not familiar with the site or what information they use to determine the quality of reviews. On Amazon we don't have control over the reviews that people leave so I'm not sure what this site bases the information on. We have asked Amazon if they would remove certain reviews that appeared to be written by competitors though if memory serves they've only agreed to remove 1 where the review was pretty egregious. - Q: Did you change the terms of the early bird investment? It was up to $200k last week and it doesn't show up anymore. - A: Hi Brian. We didn't change the terms of the early bird. What happened was that a couple people invested large amounts and because of the amounts it didn't post to the profile until WeFunder was able to confirm the investments. Even though the investments hadn't posted to the profile, they already took us over the $200k early bird amount.